These findings may open new perspectives to use CD235a+ PS+ RBC-derived EVs in T2D patients with HF in stratification at risk AF and perhaps to recognize these pro-coagulant particles as target to be serially evaluated. This evidence concerns the gene GYPA and hydrops fetalis.